LEHI, Utah, and LOUISVILLE, Ky., July 9, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, announced today that it will report financial results for the second quarter ended June 30, 2025, after market close on Wednesday, July 30, 2025. The company will discuss its financial results on a conference call at 4:30 p.m. Eastern Time that same day.
A live audio webcast of the conference call will be available on Waystar's investor relations website at https://investors.waystar.com/news-events/events. The webcast will be archived on the site for those unable to listen in real time.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$37.64 |
Daily Change: | -0.25 -0.66 |
Daily Volume: | 991,631 |
Market Cap: | US$6.510B |
April 30, 2025 April 30, 2025 April 23, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load